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To the editor: 
 
Survival of patients with sickle cell disease (SCD) in high-income countries has improved 
greatly in the last 60 years. In 1960, it was described as a “disease of childhood”
1
 while 25 
years later, the Cooperative Study of Sickle Cell Disease reported that 85% HbSS patients 
lived to adulthood. More recently, the estimate is 99% in London,
2
 97% in Paris
3
, and 94% 
in the United States.
4
 
 
Survival estimates have continued to improve; in 1994, the median survival for patients 
with HbSS/Sβ
0
 thalassemia was estimated at 42-48 years,
5
 increasing to 53-58 years in 
Jamaica in 2001
6
 and 58 years in the USA in 2014.
7
 Nonetheless, the life expectancy of 
patients with SCD is still shortened by more than 2 decades compared to the general 
population.
8-10
  
 
The present study evaluates survival among adult patients with SCD followed at a single 
center in the UK. The study was an audit of clinical practice, and involved analysis of data 
collected in routine clinical care. All procedures followed were in accordance with the 
ethical standards of the Helsinki Declaration of 1975, as revised in 2008. 712 adult (16-80 
years) patients with SCD at King’s College Hospital, London, UK, were observed over 10 
years (2004-13 inclusive) and mortality outcome identified (5268 patient-years of 
observation, median eight years of observation/patient).  
 
All patients, except for one, were of African or African-Caribbean heritage. Of the 712 
patients, there were 444 (62%) HbSS, 229 (32%) HbSC, 33 (5%) HbSβ
+
 thalassemia, and 6 
(1%) HbSβ
0
 patients. For sub-analysis, we considered HbSS and HbSβ
0
 thalassemia patients 
as a group. The median age for HbSS/Sβ
0
 patients was 32 years (IQR: 25-43); HbSC, 39 
years (IQR: 29-48); and HbSβ
+
 thalassemia, 40 years (IQR: 31-58). α-globin genotypes were 
available in 542 (76%) patients of which 62% were αα/αα, 32% αα/α-, and 5% α-/α- 
genotypes. During the study period, 72 (all HbSS) patients had received hydroxyurea 
therapy, and 71 patients had received regular blood transfusion. We underline the low 
uptake of hydroxyurea therapy in our cohort. Oxygen saturations by pulse oximetry and 
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laboratory data collected during outpatient clinic attendance were documented. 
Laboratory results were averaged over the 10-year period to create a “steady state” value 
for each patient. The mean number of hospital admissions under hematology for each 
patient was calculated from the total admissions/number of observed years of admissions. 
Local hospitals were contacted to identify outcome in patients not seen in 2012 or 2013; 
despite this, 104 (14.6%) were not reviewed in 2012 or 2013. Data collection finished on 
31 July 2015. 
 
IBM SPSS Statistics 22 was used for statistical analyses. Continuous variables were log 
transformed where necessary to obtain normalised distributions. Kaplan Meier survival 
analysis considered non-fatal cases as censored at their last clinic visit. Univariate Cox 
regression analysis was undertaken for the HbSS/Sβ
0
 subgroup only to identify risk factors 
for mortality. Dichotomous variables were handled as follows: α-thalassemia, default=no; 
sex, default=male; fetal hemoglobin (HbF) based on median split of validated HbF values 
(default HbF<5.5%); iron overload based on ferritin>1000µg/L, default=no; mean 
hospitalization rate, default ≤0.5admissions/year. We chose this cut-off based on the very 
skewed data distribution: it is clinically meaningful (equivalent to 1 admission every two 
years) and to ensure we had large enough numbers in the “high admission rate” group for 
statistical analyses. 
 
During the study period, 43 of the 712 patients (6.0%) died at a median age of 42 years 
(IQR: 31-48). They included 33 deaths in the 450 HbSS/HbSβ
0
 (7.3%) group, at median age 
41 years (IQR: 30-47), and eight deaths in 229 HbSC patients (3.5%), at median age 46 
years (31-72). For the HbSS/HbSβ
0
 group, Kaplan Meier analysis gave an estimated median 
survival of 67 years (CI 55-78 years); significantly lower than in HbSC (p<0.001, figure 1A). 
For HbSS/HbSβ
0
, there was a 90% estimated survival to 45 years (39-51), 80% to 51 years 
(CI 44-57), and 70% to 60 years (CI 51-69). 
 
Sub-analysis was undertaken for the HbSS/HbSβ
0
 subgroup; the sample size in HbSC 
subgroup was too small. Median survival in patients with high hospital admission rates 
For personal use only.on August 17, 2016. by guest  www.bloodjournal.orgFrom 
Survival in adults with SCD  Gardner et al 4 
(>0.5 admissions/year) was 60 years (CI: 43-77), significantly lower than that in patients 
with low admission rates (≤0.5/year) (p=0.001, figure 1B).  
 
Univariate Cox regression analysis (Table 1A) revealed that neither α-thalassemia nor sex 
were significant risk factors for death. Lack of difference in survival between the sexes may 
be due to the low numbers of deaths.  Hospitalization frequency was a simple but strong 
predictor of survival in SCD; the risk of death was more than 3-fold if patients had high 
frequency admissions compared to those with low admission rate. Neither hydroxyurea 
nor blood transfusion was associated with mortality. This likely reflects both the relatively 
low use of these therapies in our cohort and also the disproportionate use of these 
therapeutic strategies in our younger patients, confounding the data. Risk of death was 
increased nearly 3-fold if baseline oxygen saturations were low (<95%). 
 
For steady state laboratory results, risk of death was increased if there was: increased WBC, 
low baseline HbF level, higher lactate dehydrogenase (LDH), higher C-reactive protein, or 
iron overload (ferritin >1000ug/L). The correlation of disease severity with iron overload 
is likely via transfusion rate; it is unclear if iron overload in itself is an independent risk 
factor. For hepatic enzymes, risk of death was increased if total bilirubin, aspartate 
transaminase (AST) or alkaline phosphatase were raised, but alanine transaminase nor γ-
glutamyl transferase affected mortality risk. This may reflect red cell rather than hepatic 
origin of bilirubin and AST. Conspicuously, AST provides more dramatic hazard ratios than 
LDH as a marker of hemolysis. Both measures of renal dysfunction (creatinine and urinary 
albumin creatinine ratio) demonstrated significant associations with mortality. 
 
Multivariate Cox regression analysis (Table 1B) was based on combining variables 
associated with risk of death in the univariate analysis, plus sex and age at the start of the 
study. Variables that remained independently significant after multivariate analysis were 
high admission rate (>0.5/year),
 
Ln Creatinine, and Ln Aspartate transaminase, each 
associated with striking hazard ratios. (Table 1B) suggesting that poor renal function, 
excess hemolysis, and frequent hospital admissions can all contribute independently to 
mortality risk in SCD. 
For personal use only.on August 17, 2016. by guest  www.bloodjournal.orgFrom 
Survival in adults with SCD  Gardner et al 5 
 
In this retrospective analysis, we have demonstrated a high estimated survival (median 67 
years) for adults with HbSS/HbSβ
0
 at a single UK center, which is markedly higher than 
recent estimates from other institutions. We speculate the reasons: close monitoring of 
patients in a specialist hematology clinic, plus regular joint care with other specialists 
(renal, hepatology, neurology, cardiology, obstetrics and orthopedics); inpatient 
management by a dedicated health-care team; on-site erythrocytapheresis; and a focused 
“transition program” to ensure safe transition of teenagers to the adult service. Four of the 
43 deaths were in patients under the age of 25 years, one from hemo-pericardium due to 
stab wound, one from cerebral hemorrhage, and two from fulminant hepatic failure. We did 
not assess the socio-economic class of each patient, but they were from a broad spectrum 
of social backgrounds. All these features are similar to other large sickle centers in the UK.  
 
We acknowledge some study limitations. As an adult-only study, exclusion of pediatric 
patients may have inflated survival estimates; however, the vast majority of SCD patients 
reach adulthood in the UK.
2
 We concede that we did not model for those “lost in transition” 
between pediatric and adult care. However, all 100 patients who turned 19 in 2008-2013 
inclusive (data from the King’s Pediatric Sickle database) have been seen in the adult clinic. 
We also recognize some missing data for those not reviewed at the end of the study period, 
despite repeated attempts to obtain information. We also acknowledge the low uptake of 
hydroxyurea in our cohort (72/450 of HbSS/HbSβ
0 
patients). 
 
While life expectancy for a patient with SCD in the UK continues to improve, it still falls  
behind that in the general population in London, where it is 80.3 years for males, and 84.2 
years for females.
11
 We confirmed known predictors of mortality in SCD including markers 
of cardiorespiratory dysfunction, renal impairment and hemolysis as well as frequent 
hospitalization rate.
5,6,12-14
 While these risk factors are not causative, they certainly 
contribute to the mortality and morbidity in SCD. These risk factors identify higher risk 
patients who perhaps should be prioritized for therapies including hydroxyurea and 
hematopoietic stem cell transplantation.  
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Legends 
Table 1A: Univariate Cox regression analysis for HbSS/HbSβ
0
 thalassemia 
Table 1B – Multivariate Cox regression analysis for HbSS/HbSβ
0
 thalassemia 
 
Figure 1: Kaplan Meier survival curves 
1A) survival curve by sickle genotype 
1B) survival curve for HbSS/Sβ
0
, by hospitalization frequency 
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Table 1A – Univariate Cox regression analysis for HbSS/HbSβ
0
 thalassemia 
 
 HbSS/HbSβ
0
 thalassemia   Hazard ratio (95% 
CI) 
p value 
Demographics α-thalassemia* 1.34 (0.67-2.71) 0.411 
Sex§ 0.67 (0.34-1.34) 0.261 
Admissions    
High admission rate (>0.5/year)
 Φ
 3.13 (1.57-6.26) 0.001 
Hydroxycarbamide use 1.48 (0.57-3.86) 0.42 
Transfusions  1.00 (0.35-2.87) 0.99 
Steady state  
O
2
 saturations 
Oxygen saturations <95% 
∞
 
2.84 (1.36-5.92) 0.005 
Hematology WBC x10
9
/L 1.18 (1.04-1.35) 0.01 
Hemoglobin g/L 0.98 (0.96-1.00) 0.07 
Platelets x10
9
/L 1.00 (0.99-1.00) 0.16 
Reticulocytes x10
9
/L 1.00 (1.00-1.00) 0.29 
Fetal hemoglobin high/low ‡ 0.44 (0.20-0.96) 0.04 
Biochemistry Lactate dehydrogenase IU/L 1.00 (1.00-1.00) 0.04 
Ln C-reactive protein mg/L 1.98 (1.16-3.38) 0.013 
Ferritin >1000ug/L† 2.52 (1.21-5.23) 0.013 
Liver enzymes Ln total bilirubin µmol/L 1.78 (1.02-3.10) 0.04 
Ln aspartate transaminase IU/L 3.84 (2.11-7.00) <0.001 
Ln alanine transaminase IU/L 2.37 (0.91-6.22) 0.08 
Ln γ-glutamyl transferase IU/L 1.44 (0.97-2.14) 0.07 
Ln alkaline phosphatase IU/L 3.24 (1.93-5.45) <0.0001 
Renal function Ln Creatinine µmol/L 2.11 (1.31-3.40) 0.002 
Ln urinary albumin creatinine ratio 
mg/mmol 
1.34 (1.07-1.68) 0.01 
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Significant hazards (risk factors) are italicized. Non-normal continuous variables were 
logged for statistical comparison. Dichotomous variables were handled as below:  
* α-thalassemia, default=no 
§ Sex, default=male 
Φ 
 Mean hospitalization rate, default ≤0.5admissions/year 
∞
 Oxygen saturations, default=normal (≥95%) 
‡  HbF based on median split of validated HbF values, default HbF<5.5% 
†  Iron overload based on ferritin>1000ug/L, default=no 
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Table 1B – Multivariate Cox regression analysis for HbSS/HbSβ
0
 thalassemia (age and sex 
as co-factors) 
 
HbSS/HbSβ
0
 thalassemia   Hazard ratio (95% CI) p value 
High admission rate (>0.5/year) 2.09 (1.02-4.29) 0.04 
Ln Creatinine 3.13 (1.83-5.33) <0.0001 
Ln Aspartate transaminase 5.82 (2.93-11.54) <0.0001 
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Figure 1A 
 
 
Figure 1B 
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